Hjem › Leverkreft (hepatocellulært karcinom) › California › Orange
Kliniske studier for Leverkreft (hepatocellulært karcinom) i Orange, CA
14 studier for Leverkreft (hepatocellulært karcinom) søker deltakere på steder i og rundt Orange (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
RekruttererFase 1/2
- Research Facility, Orange
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
RekruttererFase 1/2
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
RekruttererFase 2
- UC Irvine Health. Chao Family Comprehensive Cancer Center, Orange
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RekruttererFase 1/2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
Rekrutterer
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekruttererFase 1/2
- Children's Hospital of Orange County, Orange
Patient-Derived Xenografts to Reduce Cancer Health Disparities
RekruttererObservasjonsstudie
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
RekruttererFase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RekruttererFase 1
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RekruttererFase 1/2
- Children's Hospital Orange County, Orange
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
RekruttererFase 2
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
RekruttererFase 1/2
- University of California Irvine Medical Center, Orange
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RekruttererFase 2
- University of California, Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Orange
Leverkreft (hepatocellulært karcinom)-studier i andre byer
- Houston, TX31 studier
- New York City, NY24 studier
- Dallas, TX19 studier
- Los Angeles, CA19 studier
- Boston, MA18 studier
- Cleveland, OH18 studier
- Chicago, IL16 studier
- Philadelphia, PA16 studier
- Pittsburgh, PA15 studier
- San Francisco, CA14 studier
- Jacksonville, FL14 studier
- San Antonio, TX13 studier
Andre studier i Orange
- Ikke-småcellet lungekreft25 studier
- Metastatisk kreft20 studier
- Kolorektal kreft16 studier
- Eggstokkreft16 studier
- Pankreaskreft15 studier
- Melanom14 studier
- Brystkreft14 studier
- Lungekreft14 studier
- Prostatakreft14 studier
- Mavekreft13 studier
- Kreft (alle typer)13 studier
- Akut myelogen leukemi13 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.